IMRIS VISIUS intraoperative MRI use enhances patient outcomes
MINNEAPOLIS, June 4, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that a published retrospective study indicates that use of VISIUS intraoperative MRI (iMRI) combined with endoscopy for transsphenoidal surgery (surgical access through the nose) increases the amount of pituitary (adenoma) tumor removal compared to conventional microscopy without iMRI. The amount of tumor removal using iMRI was also associated with longer patient survival, according to the article.
The retrospective study comparing 446 patients at Barnes-Jewish Hospital in St. Louis published online in the journal Pituitary showed that iMR revealed that tumor removal was incomplete for 56 out of 156 patients (35.9 percent). Since this additional tumor was discovered by intraoperative MR rather than postoperative MR, the surgery was able to continue to remove additional tumor. For 15 of these patients (or 9.6 percent), the article states, this additional tumor removal changed their outcome classification which significantly improved the progression-free survival rate for these patients.
"We found in this analyses that the endoscopy and iMRI have a complementary role in increasing resection in procedures with transsphenenoidal approaches," said Dr. Michael Chicoine, one of the study authors and associate professor of neurosurgery at the Washington University School of Medicine. "While follow up of our patients is ongoing, the data suggest that extent of resection can be used as a suitable measure of long-term survival and quality of life."The extent of tumor removal results are similar to published studies focused on removing brain tumors accessed through the skull which report that in 55% of glioma tumor cases, the surgeon resected additional tumor after iMRI. In addition, a 2011 iMRI study led by Dr. Chicoine showed that 93 percent of iMRI cases had gross total resection while 65 percent of non-iMRI surgeries achieved total resection.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV